Blockade of TIGIT-PVR Axis can Treat Breast Cancer

Autores/as

  • Ana Hernandez Garcia University of Kansas, School of Professional Studies, Biotechnology

DOI:

https://doi.org/10.17161/mjusc.v1i1.18570

Palabras clave:

TIGIT, Checkpoint Inhibitor, Cancer, Breast, PVR, immunology

Resumen

This review covers the identification and application of anti-TIGIT antibodies as checkpoint inhibitors for the treatment of triple-negative breast cancers. The original article, Targeting the TIGIT-PVR Immune Checkpoint Axis as Novel Therapeutic Option in Breast Cancer, was published by Stamm et al. in Oncoimmunology in October of 2019.

Cover of issue 1 of the Midwestern Journal of Undergraduate Sciences showing an illustration of checkpoint inhibitors

Descargas

Publicado

2022-10-03

Número

Vol. 1 Núm. 1 (2022)

Sección

Reviews

Licencia

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.

© The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license. 

Cómo citar

Hernandez Garcia, A. (2022). Blockade of TIGIT-PVR Axis can Treat Breast Cancer. Midwestern Journal of Undergraduate Sciences, 1(1), 5. https://doi.org/10.17161/mjusc.v1i1.18570